Bullish Prospects For ImmunoGen Inc. (NASDAQ: IMGN) Shares In 2022

ImmunoGen Inc. (NASDAQ:IMGN) price on Wednesday, July 27, rose 3.90% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $5.33.

A look at the stock’s price movement, the close in the last trading session was $5.13, moving within a range at $5.09 and $5.34. The beta value (5-Year monthly) was 1.24. Turning to its 52-week performance, $7.77 and $3.10 were the 52-week high and 52-week low respectively. Overall, IMGN moved 21.41% over the past month.

3 Tiny Stocks Primed to Explode
The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


ImmunoGen Inc.’s market cap currently stands at around $1.24 billion, with investors looking forward to this quarter’s earnings report slated for Feb 10, 2022 – Feb 14, 2022. Analysts project the company’s earnings per share (EPS) to be -$0.22, which has seen fiscal year 2022 EPS growth forecast to increase to -$0.82 and about -$0.73 for fiscal year 2023. Per the data, EPS growth is expected to be -20.60% for 2022 and 11.00% for the next financial year.

Analysts have a consensus estimate of $16.18 million for the company’s revenue for the quarter, with a low and high estimate of $10 million and $40.19 million respectively. The average forecast suggests down to a -4.50% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue for 2022 to grow to $85.73 million, representing a 22.70% jump on that reported in the last financial year.

Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was 7 upward and no downward review(s). Turning to the stock’s technical picture we see that short term indicators suggest on average that IMGN is a 50% Buy. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in Hold category.

10 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 3 analyst(s) rate the stock as a Hold, 7 recommend IMGN as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Overweight which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.

IMGN’s current price about 6.14% and 25.57% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 61.70, while 7-day volatility ratio is 5.45% and 6.50% in the 30-day chart. Further, ImmunoGen Inc. (IMGN) has a beta value of 1.02, and an average true range (ATR) of 0.32. Analysts have given the company’s stock an average 52-week price target of $11.38, forecast between a low of $4.00 and high of $20.00. Looking at the price targets, the low is 24.95% off current price level while to achieve the yearly target high, price needs to move -275.23%. Nonetheless, investors will most likely welcome a -125.14% jump to $12.00 which is the analysts’ median price.

In the market, a comparison of ImmunoGen Inc. (IMGN) and its peers suggest the former has performed considerably stronger. Data shows IMGN’s intraday price has changed 3.90% in last session and -3.62% over the past year. Comparatively, Eli Lilly and Company (LLY) has moved -0.79% on the day and only 35.04% in the past 12 months. Looking at another peer, we see that Sanofi (SNY) price has gained 1.13% on the day. However, the stock is -0.79% off its price a year ago. Moreover, Bristol-Myers Squibb Company (BMY) is also up 1.60% in trading on the day while keeping a an uptrend of 10.85% over the past year. Elsewhere, the overall performance for the S&P 500 and Dow Jones Industrial shows that the indexes are up 2.62% and 1.37% respectively in the last trading.

If we refocus on ImmunoGen Inc. (NASDAQ:IMGN), historical trading data shows that trading volumes averaged 2.56 million over the past 10 days and 3.75 million over the past 3 months. The company’s latest data on shares outstanding shows there are 253.26 million shares.

The 0.30% of ImmunoGen Inc.’s shares are in the hands of company insiders while institutional holders own 94.60% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 16.94 million on Apr 28, 2022, giving us a short ratio of 5.63. The data shows that as of Apr 28, 2022 short interest in ImmunoGen Inc. (IMGN) stood at 7.68% of shares outstanding, with shares short rising to 16.34 million registered in Mar 30, 2022. Current price change has pushed the stock -28.17% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the IMGN stock continues to rise going into the next quarter.

Leave a Reply

Your email address will not be published. Required fields are marked *